share_log
  • 要聞
  • Spectral AI 宣佈遵守納斯達克上市規則，市場價值持續增長。

Spectral AI Announces Compliance With Nasdaq Listing Rule Amid Continued Growth in Market Value

Spectral AI Announces Compliance With Nasdaq Listing Rule Amid Continued Growth in Market Value

Spectral AI 宣佈遵守納斯達克上市規則，市場價值持續增長。
Quiver Quantitative ·  12/14 01:00

Spectral AI confirms compliance with Nasdaq market value requirements after exceeding $35 million in market capitalization for ten days.

Spectral AI確認在市值超過3500萬後，符合納斯達克市場價值要求，已持續十天。

Quiver AI Summary

Quiver AI 概要

Spectral AI, a Dallas-based company specializing in AI-driven medical diagnostics for wound care, announced that it has regained compliance with Nasdaq Listing Rule 5550(b)(2) by maintaining a market value of over $35 million for the past 10 consecutive trading days. This follows the company's development of the DeepView System, which utilizes multi-spectral imaging to assess burn healing potential, and received Breakthrough Device Designation from the FDA in 2018. The company is now awaiting confirmation from Nasdaq regarding its compliance status. Spectral AI aims to improve treatment decisions and patient outcomes in wound care through its innovative technology.

Spectral AI是一家總部位於達拉斯的公司，專注於人工智能驅動的傷口護理醫療診斷。該公司宣佈，通過在過去的10個連續交易日內保持超過3500萬的市場價值，已重新符合納斯達克上市規則5550(b)(2)。這得益於公司開發的DeepView系統，該系統利用多光譜成像評估燒傷癒合潛力，並於2018年獲得FDA的突破性設備認證。該公司現在在等待納斯達克對其合規狀態的確認。Spectral AI旨在通過其創新技術改善傷口護理中的治療決策和患者結果。

Potential Positives

潛在的積極因素

  • Spectral AI has regained compliance with Nasdaq Listing Rule 5550(b)(2), which strengthens its position in the stock market and assures investors of its market value stability.
  • The company's market value has exceeded $35 million for the last 10 consecutive business days, indicating improved investor confidence and market perception.
  • The DeepView System, which uses advanced AI for predicting burn healing potential, continues to support the company's innovative approach in the medical diagnostics field, potentially leading to enhanced patient care and market differentiation.
  • Spectral AI已重新符合納斯達克上市規則5550(b)(2)，這加強了其在股票市場的地位，並確保投資者對其市場價值的穩定性。
  • 公司的市場價值在過去的10個連續工作日內已超過3500萬，顯示出投資者信心和市場認知的改善。
  • DeepView系統利用先進的人工智能預測燒傷癒合潛力，持續支持公司在醫療診斷領域的創新方法，有望提高患者護理和市場差異化。

Potential Negatives

潛在負面因素

  • The announcement of regaining compliance with Nasdaq Listing Rule 5550(b)(2) indicates that the company had previously been at risk of delisting, which could signal financial instability or struggles in maintaining investor confidence.
  • The emphasis on the company's need to regain compliance may raise questions about its overall financial health and market perception, especially given that such compliance issues can affect investor relations.
  • The forward-looking statements regarding the company's future plans and strategies come with significant disclaimers about the risks and uncertainties involved, suggesting that there may be challenges ahead that could impact performance and growth.
  • 遵守納斯達克上市規則5550(b)(2)的公告表明，該公司之前曾面臨退市風險，這可能表明財務不穩定或投資者信心維持方面的困難。
  • 公司需要重新獲得合規性的強調可能會引發有關其整體財務健康和市場認知的問題，特別是考慮到這樣的合規問題可能影響投資者關係。
  • 關於公司未來計劃和策略的前瞻性聲明附帶了關於風險和不確定性的重大免責聲明，表明可能面臨的挑戰可能會影響業績和增長。

FAQ

常見問題

What is Spectral AI's recent compliance announcement?

Spectral AI最近的合規公告是什麼？

Spectral AI has announced it has regained compliance with Nasdaq Listing Rule 5550(b)(2), with a market value exceeding $35 million.

Spectral AI宣佈其已重新獲得遵守納斯達克上市規則5550(b)(2)，市值超過3500萬。

What does the DeepView System do?

DeepView系統的功能是什麼？

The DeepView System uses multi-spectral imaging to predict burn healing potential, aiding in medical diagnostics and treatment decisions.

DeepView系統利用多光譜成像來預測燒傷癒合潛力，幫助醫療診斷和治療決策。

When did the DeepView System receive FDA designation?

DeepView系統何時獲得FDA認證？

The DeepView System received Breakthrough Device Designation from the U.S. FDA in 2018.

DeepView系統於2018年獲得美國FDA的突破性醫療器械認證。

What is the focus of Spectral AI?

Spectral AI的重點是什麼？

Spectral AI focuses on predictive AI for medical diagnostics, particularly in wound care including burns and diabetic foot ulcers.

Spectral AI專注於用於醫療診斷的預測人工智能，特別是在傷口護理方面，包括燒傷和糖尿病足潰瘍。

How can I learn more about DeepView?

我如何能了解更多關於DeepView的信息？

For more information about DeepView, visit the company's website at .

有關DeepView的更多信息，請訪問該公司的網站。

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

免責聲明：這是由GlobeNewswire分發的新聞稿的人工智能生成摘要。用於總結這份稿件的模型可能會出錯。請在這裏查看完整發布。


$MDAI Hedge Fund Activity

$MDAI對沖基金活動

We have seen 12 institutional investors add shares of $MDAI stock to their portfolio, and 10 decrease their positions in their most recent quarter.

我們看到12個機構投資者在最近一個季度中增加了$MDAI股票的持股，10個減少了他們的持倉。

Here are some of the largest recent moves:

以下是最近的一些重大變動：

  • MORGAN STANLEY added 110,727 shares (+3261.5%) to their portfolio in Q3 2024
  • AVANTAX PLANNING PARTNERS, INC. added 95,493 shares (+148.4%) to their portfolio in Q3 2024
  • VANGUARD GROUP INC added 43,872 shares (+71.3%) to their portfolio in Q3 2024
  • MURCHINSON LTD. removed 40,000 shares (-100.0%) from their portfolio in Q2 2024
  • UBS GROUP AG added 39,105 shares (+3910500.0%) to their portfolio in Q3 2024
  • GEODE CAPITAL MANAGEMENT, LLC added 29,527 shares (+43.9%) to their portfolio in Q3 2024
  • MYDA ADVISORS LLC removed 20,000 shares (-100.0%) from their portfolio in Q2 2024
  • 摩根士丹利在2024年第三季度增加了110,727股（+3261.5%）的持股。
  • AVANTAX PLANNING PARTNERS, INC.在2024年第三季度增加了95,493股（+148.4%）的持股。
  • 先鋒集團在2024年第三季度增加了43,872股（+71.3%）的持股。
  • MURCHINSON LTD.在2024年第二季度減少了40,000股（-100.0%）的持股。
  • 瑞銀在2024年第三季度增加了39,105股（+3910500.0%）的持股。
  • GEODE CAPITAL MANAGEMENT, LLC在2024年第三季度新增29,527股(+43.9%)
  • MYDA ADVISORS LLC在2024年第二季度減持20,000股(-100.0%)

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

要跟蹤對沖基金的股票投資組合，請查看Quiver Quantitative的機構持有情況儀表。

Full Release

完整發布



DALLAS, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) ("Spectral AI" or the "Company"), developer of the AI-driven DeepView



System, which received Breakthrough Device Designation from the U.S. FDA in 2018, that uses multi-spectral imaging and algorithms to predict burn healing potential, today announced today that the Company believes it has regained compliance with Nasdaq Listing Rule 5550(b)(2), which requires listed companies to maintain a minimum market value of listed securities of $35 million.


達拉斯，2024年12月13日（環球新聞）-- 光譜人工智能（納斯達克：MDAI）（"光譜人工智能"或"公司"），人工智能驅動的DeepView系統開發者，



該系統於2018年獲得美國FDA的突破性醫療器械設計認證，利用多光譜成像和算法預測燒傷癒合潛力，今天公司宣佈相信已重新符合納斯達克上市規則5550(b)(2)的要求，該規則要求上市公司保持至少3500萬美元的上市證券最低市場價值。



The market value of Spectral AI's common stock has exceeded $35 million at the close of trading for the last 10 consecutive business days, as required by Nasdaq rules. The company has notified Nasdaq of its compliance and is awaiting confirmation from the exchange.


根據納斯達克的規則，光譜人工智能的普通股市場價值在過去10個連續的交易日結束時已超過3500萬美元。公司已通知納斯達克其合規性，並正在等待交易所的確認。




About Spectral AI



本新聞稿中的某些聲明是「前瞻性聲明」，在美國《私人證券訴訟改革法》第21E條的「安全港」規定下進行。這些前瞻性聲明涉及到公司的策略、計劃、目標、倡議和財務展望。在本新聞稿中使用的「估計」、「預計」、「預測」、「計劃」、「打算」、「相信」、「尋求」、「可能」、「將」、「應該」、「未來」、「建議」及其變體或類似表達（或這些單詞或表達的否定版本）旨在識別前瞻性聲明。



Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by "Seeing the Unknown



" with its DeepView



System. DeepView is a predictive device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, DeepView is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView, visit



.


Spectral AI, Inc.是一家位於達拉斯的預測人工智能公司，專注於醫療診斷，以便更快速和準確地爲傷口護理作出治療決策，最初的應用涉及燒傷和糖尿病足潰瘍患者。該公司正在努力通過「看見未知」來革新傷口護理的管理。



與其DeepView系統。



DeepView是一個預測設備，能夠在治療或其他醫療干預之前，客觀、即時地評估傷口的癒合潛力。通過算法驅動的結果及在未來超越當前護理標準的目標，DeepView預計將提供更快速、更準確的治療洞察，從而改善患者的治療效果，降低醫療成本。有關DeepView的更多信息，訪問



.




Forward-Looking Statements



前瞻性聲明



Certain statements made in this release are "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company's intention to separate its Spectral IP subsidiary from the Company, and each Company's strategy, plans, objectives, initiatives, strategic goals, financial outlook or other non-historical matters. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.


Certain statements made in this release are "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company's intention to separate its Spectral IP subsidiary from the Company, and each Company's strategy, plans, objectives, initiatives, strategic goals, financial outlook or other non-historical matters. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.



These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.


These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.



Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" sections of the Company's filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Spectral AI undertakes no obligation to update any forward-looking statements except as otherwise required by law.


投資者應仔細考慮上述因素以及公司在向美國證券交易委員會提交的文件中描述的其他風險和不確定性，包括註冊聲明和公司提交的其他文件。這些文件識別並處理其他重要風險和不確定性，這些風險和不確定性可能導致實際事件和結果實質性偏離前瞻性聲明中包含的內容。除法律要求外，Spectral AI不承擔更新任何前瞻性聲明的義務。



For Media and Investor Relations, please contact:


如需媒體和投資者關係信息，請聯繫：



David Kugelman
Atlanta Capital Partners LLC
(866) 692-6847 Toll Free - U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Email:

dk@atlcp.com


大衛·庫格爾曼
亞特蘭大資本合作伙伴有限公司
(866) 692-6847 免費電話 - 美國及加拿大
(404) 281-8556 手機和WhatsApp
電子郵件：

dk@atlcp.com



声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間